Geron Announces Submission Of New Drug Application To FDA For First-in-Class Telomerase Inhibitor Imetelstat
Portfolio Pulse from Benzinga Newsdesk
Geron Corporation has submitted a New Drug Application (NDA) to the FDA for its first-in-class telomerase inhibitor, Imetelstat. The drug aims to treat patients with myelofibrosis, a rare bone marrow cancer.
June 20, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron Corporation submitted an NDA to the FDA for Imetelstat, a first-in-class telomerase inhibitor. This could potentially lead to a new treatment option for myelofibrosis patients.
The submission of the NDA for Imetelstat is a significant milestone for Geron Corporation. If approved, it could lead to a new treatment option for myelofibrosis patients, potentially increasing the company's revenue and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100